NCT05897515

LIAISON NES Influenza (FLU) A/B & Coronavirus Disease 2019 (COVID-19) Clinical Agreement in Australia

LIAISON NES Flu A/B & COVID-19 Clinical Agreement in Australia

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 233 (actual)
• Sponsor: DiaSorin Molecular LLC · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The DiaSorin Molecular LIAISON® NES FLU A/B \& COVID-19 real-time polymerase chain reaction (RT-PCR) assay is intended for use on the DiaSorin LIAISON® NES instrument for the in-vitro qualitative detection and differentiation of nucleic acid from influenza A, influenza B and SARS-CoV-2 virus from dry nasal swabs (NS) from human patients with signs and symptoms during the acute phase of respiratory tract infection in conjunction with clinical and epidemiological risk factors. The LIAISON® NES FLU A/B \& COVID-19 assay is intended for use as an aid in the differential diagnosis of influenza A, influenza B and SARS-CoV-2 infection in a professional laboratory setting. Negative results do not preclude influenza A, influenza B, or SARS-CoV-2, infection and should not be used as the sole basis for patient management decisions. The assay is not intended to detect the presence of the influenza C virus.

Conditions

• Influenza A
• Influenza Type B
• Coronavirus Disease 2019

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	LIAISON NES FLU A/B & COVID-19	The LIAISON® NES FLU A/B \& COVID-19 assay used on the LIAISON® NES instrument is a real-time PCR system that enables the direct amplification, detection and differentiation of Flu A viral RNA, Flu B viral RNA and SARS-CoV-2 RNA from dry nasal swabs. Nasal Swabs can be professionally collected by a Healthcare Provider or self-collected by the patient under the supervision of the healthcare provider. The collected nasal swab can then be directly loaded into the cartridge without nucleic acid extraction.

Timeline

• Start date: 2023-06-19
• Primary completion: 2023-09-15
• Completion: 2023-10-31
• First posted: 2023-06-09
• Last updated: 2024-04-30

Locations

1 site across 1 country: Australia